Tumor necrosis factor-α in vitiligo: direct correlation between tissue levels and clinical parameters

Kim, Nancy H.; Torchia, Daniele; Rouhani, Panta; Roberts, Bill; Romanelli, Paolo

doi:10.3109/15569527.2011.560913

Cited by 46 publications

(43 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cases of vitiligo treated with TNF-α inhibitors, although achieving mixed results, have been reported as well (Rigopoulos et al, 2007;Campanati et al, 2010). A recent study has shown that the anti-TNF-α agent etanercept can stop vitiligo progression and induce repigmentation in some cases (Kim et al, 2011). In vitro direct analyses of skin T cells from the margins of vitiliginous skin have shown that polarized type-1 T cells (CD4+ and CD8+), which secrete predominantly TNF-a and interferon-g, are associated with the destruction of melanocytes during active vitiligo (Huang et al, 2002;Wankowicz-Kalinska et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with vitiligo

Al-Harthi

Zouman²,

Arfin³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Vitiligo is an acquired depigmentary disorder of the skin, characterized by multiple susceptibility loci and genetic heterogeneity. The etiology of vitiligo is unknown but several hypotheses, including an autoimmune origin, have been proposed. Tumor necrosis factor (TNF)-α, a pleiotropic proinflammatory cytokine, has been shown to play a critical role in several autoimmune diseases including vitiligo. The aim of present study was to determine the association of TNF-α and -β gene polymorphisms with vitiligo in Saudi patients. TNF-α and -β genes were amplified in 123 Saudi patients and 200 matched controls using polymerase chain reaction to search for polymorphisms involved at positions -308, and intron 1 +252. The frequency of the TNF-α (-308) GA genotype was higher and the frequencies of the GG and AA genotypes were significantly lower in vitiligo patients compared to controls. These findings suggested that genotype GA-positive individuals at position -308 of TNF-α are susceptible to vitiligo, whereas the GG and AA genotypes might exert a protective effect. The frequency of allele A (TNF-α 2-allele) was significantly higher and that of allele G (TNF-α 1-allele) was lower in vitiligo patients compared to controls, indicating an association of allele A with susceptibility to TNF-α and -β polymorphisms in vitiligo vitiligo in Saudi patients. The results of our examination of TNF-β (intron 1 +252) polymorphisms showed a significant increase in the frequency of the GG genotype and allele G (TNF-b 1-allele) in vitiligo patients, suggesting a susceptibility of the GG genotype and allele G for vitiligo. By contrast, the high frequency of the GA genotype in controls might indicate a protective effect. The results of the present study strongly support a link between TNF-α (-308) and -β (intron 1 +252) polymorphisms and vitiligo in Saudi patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This phenomenon is akin to that of other common skin inflammatory disorders such as psoriasis and atopic dermatitis (Taieb, 2012). Moreover, ample evidence suggests that cytokines, particularly tumor necrosis factors (TNFs) play a role in the depigmentation process of vitiligo (Moretti et al, 2002;Namian et al, 2009;Kim et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with vitiligo

Al-Harthi

Zouman²,

Arfin³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Experimental evidences have shown a role of tumor necrosis factor (TNF)-a in the pathogenesis of non-segmental vitiligo; in fact, successful treatment of vitiligo with TNF-a inhibitors has been recently reported. 5 Cutaneous depigmentation involves cytotoxic activity of autoreactive T-cells; it was hypothesized that depigmentation can progress when the activity of regulatory T-cells (Treg) is reduced. A reduced percentage of Treg in non-lesional, perilesional, and lesional vitiligo skin was observed through an evaluation by immunoenzymatic double-staining for CD3 and FoxP3.…”

Section: Introductionmentioning

confidence: 99%

Increased serum levels of interleukin‐23 circulating in patients with non‐segmental generalized vitiligo

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Some resistant generalized cases were associated with high skin levels of TNF-alpha, and improvement with TNF-alpha inhibitors like etanercept is reported [9]. …”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Efficacy of Topical Tetracycline in Enhancing the Effect of Narrow Band UVB against Vitiligo: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Kalafi

Jowkar

2014

ISRN Dermatology

View full text Add to dashboard Cite

Background. Vitiligo is a pigmentary disorder characterized by depigmented macules due to absence of melanocytes. Increased levels of tumor necrosis factor alpha and interleukin-1 in the epidermis of lesions may play a role in keratinocyte apoptosis and less production of melanogenic cytokines. Tetracyclines reduce production of tumor necrosis factor alpha and interleukin-1. Objective. To evaluate the effect of topical tetracycline on vitiligo patients on phototherapy. Methods. Thirty cases of generalized stable vitiligo were chosen randomly and pigmentation of two assigned lesions on right and left sides (same size and location) was determined by vitiligo area severity index, and medication and placebo were randomly assigned to be applied twice daily on either right or left side, respectively. Images were taken of the lesions at the end of the 4th, 8th, and 12th weeks and pigmentations were compared to baseline using aforementioned index. The patients also took narrow band ultraviolet B two to three times a week. Results. Mean pigmentation, based on vitiligo area severity index, changed significantly from 90.1667 to 86.6667 (P = 0.026) and on placebo side from 89.6667 to 86.8333 (P = 0.026). There was no significant difference between medication and placebo sides in terms of pigmentation (P = 0.566). Conclusions. No significant difference in improving repigmentation between medication and placebo sides was seen.

show abstract

Tumor necrosis factor-α in vitiligo: direct correlation between tissue levels and clinical parameters

Cited by 46 publications

References 10 publications

Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with vitiligo

Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with vitiligo

Increased serum levels of interleukin‐23 circulating in patients with non‐segmental generalized vitiligo

Evaluation of the Efficacy of Topical Tetracycline in Enhancing the Effect of Narrow Band UVB against Vitiligo: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Contact Info

Product

Resources

About